Patents by Inventor Martin Haraldsson
Martin Haraldsson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11795157Abstract: There is herein provided a compound of formula I or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer and/or the treatment or prevention of a viral infection, wherein A1, A2, L1, R1, R2 and n have meanings as provided in the description.Type: GrantFiled: January 8, 2021Date of Patent: October 24, 2023Inventors: Sonia Lain, Catherine Drummond, Ingeborg Van Leeuwen, Martin Haraldsson, Lars Johansson, Lars Sandberg, Ulrika Yngve
-
Publication number: 20230110478Abstract: A compound of formula I or a pharmaceutically acceptable salt thereof. The compound is useful in therapy, e.g. for the treatment of cancers, inflammation, autoimmune diseases and graft-versus host diseases (e.g. in transplantation patients). A pharmaceutical composition comprising the compound or its salt and a method for preparing the compound.Type: ApplicationFiled: October 14, 2022Publication date: April 13, 2023Inventors: Christoffer BENGTSSON, Sanjay BORHADE, Martin HARALDSSON, Thomas HELLEDAY, Martin HENRIKSSON, Evert HOMAN, Cynthia PAULIN, Lars SANDBERG, Martin SCOBIE, Pål STENMARK, Karl VALLIN
-
Patent number: 11504368Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof. The compound is useful in therapy, e.g. for the treatment of cancers, inflammation, autoimmune diseases and graft-versus host diseases (e.g. in transplantation patients). A pharmaceutical composition comprising the compound or its salt and a method for preparing the compound.Type: GrantFiled: April 17, 2019Date of Patent: November 22, 2022Assignee: THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNINGInventors: Christoffer Bengtsson, Sanjay Borhade, Martin Haraldsson, Thomas Helleday, Martin Henriksson, Evert Homan, Cynthia Paulin, Lars Sandberg, Martin Scobie, Pål Stenmark, Karl Vallin
-
Publication number: 20210230141Abstract: There is herein provided a compound of formula I or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer and/or the treatment or prevention of a viral infection, wherein A1, A2, L1, R1, R2 and n have meanings as provided in the description.Type: ApplicationFiled: January 8, 2021Publication date: July 29, 2021Inventors: Sonia Lain, Catherine Drummond, Ingeborg Van Leeuwen, Martin Haraldsson, Lars Johansson, Lars Sandberg, Ulrika Yngve
-
Publication number: 20210052587Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof. The compound is useful in therapy, e.g. for the treatment of cancers, inflammation, autoimmune diseases and graft-versus host diseases (e.g. in transplantation patients). A pharmaceutical composition comprising the compound or its salt and a method for preparing the compound.Type: ApplicationFiled: April 17, 2019Publication date: February 25, 2021Inventors: Christoffer BENGTSSON, Sanjay BORHADE, Martin HARALDSSON, Thomas HELLEDAY, Martin HENRIKSSON, Evert HOMAN, Cynthia PAULIN, Lars SANDBERG, Martin SCOBIE, Pål STENMARK, Karl VALLIN
-
Patent number: 10889564Abstract: There is herein provided a compound of formula I (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer and/or the treatment or prevention of a viral infection, wherein A1, A2, L1, R1, R2 and n have meanings as provided in the description.Type: GrantFiled: November 1, 2016Date of Patent: January 12, 2021Assignee: Genase Therapeutics B.V.Inventors: Sonia Lain, Catherine Drummond, Ingeborg Van Leeuwen, Martin Haraldsson, Lars Johansson, Lars Sandberg, Ulrika Yngve
-
Publication number: 20190152943Abstract: There is herein provided a compound of formula I (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer and/or the treatment or prevention of a viral infection, wherein A1, A2, L1, R1, R2 and n have meanings as provided in the description.Type: ApplicationFiled: November 11, 2016Publication date: May 23, 2019Inventors: Sonia Lain, Catherine Drummond, Ingeborg van Leeuwen, Martin Haraldsson, Lars Johansson, Lars Sandberg, Ulrika Yngve
-
Patent number: 9227967Abstract: Disclosed are compounds which inhibit SSAO enzyme activity. Also disclosed are pharmaceutical compositions comprising these compounds and the use of these compounds in the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases, immune disorders and the inhibition of tumor growth.Type: GrantFiled: March 14, 2011Date of Patent: January 5, 2016Assignee: Proximagen LimitedInventors: David Evans, Allison Carley, Alison Stewart, Michael Higginbottom, Edward Savory, Iain Simpson, Marianne Nilsson, Martin Haraldsson, Erik Nordling, Tobias Koolmeister
-
Patent number: 9150574Abstract: 2-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}ethan-1-amine; 3-aminopropyl 4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxylate; 1-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}-4-(dimethylamino)butan-1-one; 5-amino-1-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}pentan-1-one; N-(2-aminoethyl)-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide; N-(3-aminopropyl)-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide; 4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-[3-(dimethylamino)propyl]piperidine-1-carboxamide; 1-({4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)piperazine; 4-({4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)morpholine; 1-({4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)-1,4-diazepane; ethyl 1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboType: GrantFiled: September 14, 2011Date of Patent: October 6, 2015Assignee: Proximagen LimitedInventors: David Evans, Allison Carley, Alison Stewart, Michael Higginbottom, Edward Savory, Iain Simpson, Marianne Nilsson, Martin Haraldsson, Erik Nordling, Tobias Koolmeister
-
Publication number: 20150239905Abstract: The invention relates to compounds of formula (I): and their pharmaceutically acceptable salts and solvates, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.Type: ApplicationFiled: May 14, 2015Publication date: August 27, 2015Inventors: Marianne Nilsson, Martin Haraldsson, Sofia Henriksson, Rikard Emond, Edward Savory, Iain Simpson
-
Publication number: 20140357623Abstract: 2-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}ethan-1-amine; 3-aminopropyl 4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxylate; 1-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}-4-(dimethylamino)butan-1-one; 5-amino-1-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}pentan-1-one; N-(2-aminoethyl)-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide; N-(3-aminopropyl)-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide; 4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-[3-(dimethylamino)propyl]piperidine-1-carboxamide; 1-({4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)piperazine; 4-({4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)morpholine; 1-({4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)-1,4-diazepane; ethyl 1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboType: ApplicationFiled: September 14, 2011Publication date: December 4, 2014Applicant: PROXIMAGEN LIMITEDInventors: David Evans, Allison Carley, Alison Stewart, Michael Higginbottom, Edward Savory, Iain Simpson, Marianne Nilsson, Martin Haraldsson, Erik Nordling, Tobias Koolmeister
-
Publication number: 20140206662Abstract: A method of treating inflammation, an inflammatory disease, an immune or an autoimmune disorder comprising administering to a patient in need thereof compounds of formula (I): and their pharmaceutically acceptable salts and solvates, which are inhibitors of SSAO activity. The compounds inhibit SSAO activity.Type: ApplicationFiled: March 13, 2014Publication date: July 24, 2014Applicant: PROXIMAGEN LTD.Inventors: Marianne Nilsson, Martin Haraldsson, Sofia Henriksson, Rikard Emond, Edward Savory, Iain Simpson
-
Publication number: 20130102587Abstract: Disclosed are compounds which inhibit SSAO enzyme activity. Also disclosed are pharmaceutical compositions comprising these compounds and the use of these compounds in the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases, immune disorders and the inhibition of tumour growth.Type: ApplicationFiled: March 14, 2011Publication date: April 25, 2013Applicant: PROXIMAGEN LIMITEDInventors: David Evans, Allison Carley, Alison Stewart, Michael Higginbottom, Edward Savory, Iain Simpson, Marianne Nilsson, Martin Haraldsson, Erik Nordling, Tobias Koolmeister
-
Publication number: 20120010188Abstract: The invention relates to compounds of formula (I): and their pharmaceutically acceptable salts and solvates, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.Type: ApplicationFiled: December 4, 2009Publication date: January 12, 2012Applicant: PROMIMAGEN LTD.Inventors: Marianne Nilsson, Martin Haraldsson, Sofia Henriksson, Rikard Emond, Edward Daniel Savory, Iain David Simpson
-
Patent number: 7666888Abstract: Compounds of formula I and IV are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorder: wherein the variables A-B, R1, R2, m, and Q are described herein.Type: GrantFiled: July 18, 2007Date of Patent: February 23, 2010Assignees: Amgen Inc., Biovitrum ABInventors: Michael D. Bartberger, Christopher H. Fotsch, Martin Haraldsson, David St. Jean, Lars Johansson, Marianne Nilsson, Lori Sutin, Katrina Flyrén
-
Publication number: 20100022590Abstract: The present invention relates to novel isoxazole compounds of formula (I), and pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides thereof, which are modulators of 11?-hydroxysteroid dehydrogenase type 1 (11?-HSD1). The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the preparation of a medicament for the treatment of glaucoma.Type: ApplicationFiled: January 15, 2009Publication date: January 28, 2010Applicant: BIOVITRUM AB (publ.)Inventors: Styrbjörn Byström, Martin Haraldsson, Lars Johansson, Jan Tejbrant
-
Publication number: 20080021022Abstract: Compounds of formula I and IV are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorder: wherein the variables A-B, R1, R2, m, and Q are described herein.Type: ApplicationFiled: July 18, 2007Publication date: January 24, 2008Inventors: Michael Bartberger, Christopher Fotsch, Martin Haraldsson, David St. Jean, Lars Johansson, Marianne Nilsson, Lori Sutin, Katrina Flyren
-
Patent number: 6313132Abstract: The invention relates to novel compounds of Formula (I) wherein R1, R2, R3, R4, R5, R6, R7 and Ar are as defined in claim 1, their salts with physiologically acceptable acids and, when the compounds can be in the form of optical isomers, the racemic mixture and the individual enantiomers. The compounds have anticholinergic activity, and the invention also relates to the compounds of Formula (I), the use of the compounds of Formula (I) for preparing anticholinergic drugs, the use of the compounds of Formula (I) for treating urinary tract incontinence, and methods for preparing the compounds of Formula (I).Type: GrantFiled: September 27, 1999Date of Patent: November 6, 2001Assignee: Pharmacia ABInventors: Rolf Johansson, Martin Haraldsson, Erik Ringberg, Ian Vagberg, Katarina Beierlein, Rikard Emond, Birger Sjoberg
-
Patent number: 6124354Abstract: This invention relates to the use of 2-(diisopropylamino)-ethyl-1-phenyl-cyclopentane-carboxylate or 2-(diisopropylamino)-ethyl-1-phenyl-cyclohexane-carboxylate, or a pharmaceutically accceptable salt thereof, for treatment of urinary incontinence or irritable bowel syndrome (IBS).Type: GrantFiled: April 12, 1999Date of Patent: September 26, 2000Assignee: Pharmacia & Upjohn ABInventors: Eva .ANG.kerblom, Martin Haraldsson, Rolf Johansson, Katarina Beierlein, Birger Sjoberg, Erik Ringberg, Birgitta Weinz
-
Patent number: 5556855Abstract: A compound of the formula Het--NR--SO.sub.2 --Ph.sup.2 --A--Ph.sup.1 (COOH)(OH) and tautomic form, salts, solvates, C.sub.1-6 alkyl esters and pharmaceutical compositions of the compound. Ph.sup.1 and Ph.sup.2 are benzene rings with the proviso that carboxy and hydroxy are ortho to one another. Het includes an optionally substituted heterocyclic ring which includes conjugated double bonds and binds to nitrogen in NR. The compound is characterized in that A is a bridge which is stable against reduction because it is not azo, and in that R is hydrogen or lower alkyl.The invention also includes the preparation of the compound and its use as a drug, particularly for treating autoimmune diseases.Type: GrantFiled: December 29, 1994Date of Patent: September 17, 1996Assignee: Pharmacia ABInventors: Hubert Agback, Leif Ahrgren, Thomas Berglindh, Martin Haraldsson, G oran Smedeg.ang.rd, Lars-Inge Olsson